Ferdinandos Skoulidis
@FSkoulidis
Followers
756
Following
20
Media
4
Statuses
13
Associate Professor of Thoracic Medical Oncology @MDAndersonNews. Views are my own. #LungCancer
Joined May 2021
Incredibly proud of my daughter Isabella Skoulidis who summited M.Kilimanjaro to raise funds for children in Sudan. The climb has ended but the cause is more urgent than ever. #summitforSUDAN
0
0
11
Climbing for a Cause: Isabella’s Journey to Mount Kilimanjaro Summit for Sudan
sapa-usa.org
14-year-old Isabella climbs Kilimanjaro to raise funds for Sudan’s children. Support life-saving aid and follow her inspiring journey, “Summit for Sudan”.
3
0
8
Summit for Sudan | SAPA - Children in Sudan are facing a humanitarian crisis. SAPA,led by @YYElamin is providing life-saving aid. My 14-yo daughter is climbing M.Kilimanjaro to raise funds & awareness. Click the link below to support her journey.Thank you!
sapa-usa.org
At 14, Isabella Skoulidis climbed Kilimanjaro to support Sudan’s children. Her journey brought vital aid—help us continue her mission. Donate now.
0
0
3
Thrilled to share this exciting study @NatureMedicine. Largest integrative analysis of #sotorasib efficacy biomarkers to date. Grateful to all co- investigators and the Amgen team for their hard work and most of all to our patients. @MDAndersonNews #KRAS #NSCLC
7
60
202
From the November issue: Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-mutant NSCLC https://t.co/qdBBP1lx8w
@_hanielaraujo, @XimoPechuan, Teng Zhou, @FSkoulidis, and colleagues @MDAndersonNews
1
4
9
Key points: ✅CTLA4 abrogates KEAP1/STK11-related PD-(L)1i resistance in NSCLC ✅Dual ICB engages CD4+ TH1/reprograms myeloid cells ✅Validation in POSEIDON. Results support 1st line dual ICB+chemo for STK11/KEAP1 MUT NSCLC #STK11 #KEAP1 #CTLA4 #NSCLC
https://t.co/UUDcrhGPj6
4
23
71
Excited to share our new study @Nature. Very grateful for the support of our collaborators, pharma and biotech partners and members of the Skoulidis and Heymach labs. Special thanks to star fellow @_hanielaraujo and @minhtruongdo. Thankful to our patients. @MDAndersonNews
21
91
336
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM https://t.co/0dMoUuuPGf
#ASCO2021 #KRAS #MDAndersonNews #Sotorasib
nejm.org
Sotorasib showed anticancer activity in patients with KRAS p.G12C–mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was observed in a subgroup of pati...
2
9
34
A big thank you to all patients and their families, clinical trial personnel and colleagues for making the practice changing CodeBreaK100 clinical trial possible. #ASCO2021 #KRAS #MDAndersonNews #Sotorasib
1
4
33
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM
nejm.org
Sotorasib showed anticancer activity in patients with KRAS p.G12C–mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was observed in a subgroup of pati...
0
0
6
“The regulatory approval of sotorasib represents a major landmark for patients with KRAS G12C-mutated lung cancer,” says Dr. Ferdinandos Skoulidis of the now @FDA-approved targeted therapy drug that's helped trial participant Steve Castellaw. https://t.co/de1i3rFFUs
#EndCancer
0
5
19
This seems like a good time to finally join twitter. On Friday 28th of May 2021 the FDA approved the first ever direct KRAS G12C inhibitor #sotorasib for patients with advanced KRAS p.G12C mutant lung cancer. After nearly 4 decades a truly historic milestone.
6
15
133